Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2743-2746
Published online before print November 17, 2003, doi: 10.1161/01.CIR.0000103680.61390.16
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/22/2743    most recent
01.CIR.0000103680.61390.16v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welzig, C. M.
Right arrow Articles by Galper, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welzig, C. M.
Right arrow Articles by Galper, J. B.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Arrythmias-basic studies

(Circulation. 2003;108:2743.)
© 2003 American Heart Association, Inc.


Brief Rapid Communications

Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate

G{alpha}i2, a Possible Molecular Marker for Parasympathetic Responsiveness

C. Michael Welzig, MD, PhD*; Dong-Gu Shin, MD, PhD*; Ho-Jin Park, PhD*; Young-Jo Kim, MD, PhD; J. Philip Saul, MD; Jonas B. Galper, MD, PhD

From The Children’s Heart Program (C.M.W., J.P.S.), Medical University of South Carolina, Charleston, SC; Department of Internal Medicine (D.-G.S., Y.-J.K.), Yeungnam University Hospital, Daegu, Korea; and Molecular Cardiology Research Institute (H.-J.P., J.B.G.), Cardiovascular Division, Department of Medicine, Tufts-New England Medical Center and Tufts Medical School, Boston, Mass.

Correspondence to Jonas B. Galper, Tufts-New England Medical Center Box #8486, 750 Washington St, Boston, MA 02111. E-mail Jgalper{at}Tufts-NEMC.org

Received March 11, 2003; de novo received August 8, 2003; revision received October 2, 2003; accepted October 6, 2003.

Background— We have previously demonstrated in an in vitro model for lipid lowering that lipoprotein depletion resulted in a marked increase in the negative chronotropic response to the acetylcholine analogue carbamylcholine. In this study we used heart rate variability analysis to determine the effect of lipid lowering by statins on the response of the heart to parasympathetic stimulation. In parallel, we examined whether changes in parasympathetic responsiveness correlated with changes in the expression of G{alpha}i2, a molecular component of the parasympathetic signaling pathway in the heart.

Methods and Results— Patients were randomized in a crossover study of pravastatin and simvastatin. R-R interval analysis of Holter monitor studies demonstrated that in patients treated initially with pravastatin, the peak high-frequency power fraction during sleep, which reflects parasympathetic modulation of heart rate, increased by 24.0±5.02% (SEM, n=13, P<0.001) compared with the untreated control value. Simvastatin had no significant effect. Western blot analysis of lymphocytes from patients treated with pravastatin demonstrated a 90.1±27.3% (n=10, P=0.009) increase in G{alpha}i2 expression, whereas simvastatin had no effect. Relative changes in G{alpha}i2 correlated significantly with the changes in the fraction of high-frequency power ({rho}=0.574, P=0.016).

Conclusions— Taken together with our in vitro data, these data are the first to suggest that cholesterol lowering by pravastatin might increase the response of the heart to parasympathetic stimulation and that changes in G{alpha}i2 expression might serve as a molecular marker for this effect.


Key Words: lipids • statins • heart rate




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
H. H.H. Feringa, O. Schouten, S. E. Karagiannis, J. Brugts, A. Elhendy, E. Boersma, R. Vidakovic, M. R.H.M. van Sambeek, P. G. Noordzij, J. J. Bax, et al.
Intensity of Statin Therapy in Relation to Myocardial Ischemia, Troponin T Release, and Clinical Cardiac Outcome in Patients Undergoing Major Vascular Surgery
J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1649 - 1656.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. E. Mager and D. R. Abernethy
Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 423 - 430.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. Schwartz, S. K. Park, M. S. O'Neill, P. S. Vokonas, D. Sparrow, S. Weiss, and K. Kelsey
Glutathione-S-Transferase M1, Obesity, Statins, and Autonomic Effects of Particles: Gene-by-Drug-by-Environment Interaction
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1529 - 1533.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. H. Shishehbor, B. J. Hoogwerf, and M. S. Lauer
Association of Triglyceride-to-HDL Cholesterol Ratio With Heart Rate Recovery
Diabetes Care, April 1, 2004; 27(4): 936 - 941.
[Abstract] [Full Text] [PDF]